NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $47.00

NewAmsterdam Pharma (NASDAQ:NAMSFree Report) had its price objective upped by Scotiabank from $35.00 to $47.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a sector outperform rating on the stock.

A number of other brokerages have also recently commented on NAMS. Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Buy” and an average target price of $36.20.

Check Out Our Latest Stock Analysis on NewAmsterdam Pharma

NewAmsterdam Pharma Price Performance

NAMS stock opened at $24.69 on Wednesday. The firm has a fifty day moving average price of $20.53 and a 200 day moving average price of $18.72. NewAmsterdam Pharma has a fifty-two week low of $9.72 and a fifty-two week high of $27.29.

Insider Buying and Selling

In other news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $25.08, for a total value of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock valued at $1,755,307 in the last ninety days. 19.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the 2nd quarter valued at $38,000. Quarry LP increased its position in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC increased its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Bellevue Group AG purchased a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd purchased a new position in NewAmsterdam Pharma in the third quarter valued at about $187,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

See Also

Analyst Recommendations for NewAmsterdam Pharma (NASDAQ:NAMS)

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.